Analytical review of diagnosis and treatment strategies for dominant bile duct strictures in patients with primary sclerosing cholangitis

HPB

Volumn 13, Issue 2, 2011, Pages 79-90

  Aljiffry, Murad ^a,b   Renfrew, Paul D ^c   Walsh, Mark J ^c   Laryea, Marie ^c   Molinari, Michele ^c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

biliary dilatation; biliary stenting; cholangiocarcinoma; DIA; dominant stricture; endoscopic ultrasound; ERCP MRCP CT cholangiography; FISH; primary sclerosing cholangitis

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

BIBLIOGRAPHIC DATABASE; BILE DUCT OBSTRUCTION; CHOLANGIOGRAPHY; COCHRANE LIBRARY; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DILATATION; DOMINANT BILE DUCT STRICTURE; EMBASE; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HUMAN; IMAGE ANALYSIS; LABORATORY TEST; LIVER FUNCTION TEST; MEDLINE; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; SENSITIVITY AND SPECIFICITY; STENT; TREATMENT DURATION;

EID: 78751669801     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2010.00268.x     Document Type: Review

References (94)

1. Lee YM, Kaplan MM,. (1995) Medical progress: primary sclerosing cholangitis. N Engl J Med 332: 924-993.
2. Nakanuma Y, Hirai N, Kono N, Ohta G,. (1986) Histological and ultrastructural examination of the intrahepatic biliary tree in primary sclerosing cholangitis. Liver 6: 317-325.
3. Broome U, Grunewald J, Scheynius A, Olerup O, Hultcrantz R,. (1997) Preferential V beta3 usage by hepatic T lymphocytes in patients with primary sclerosing cholangitis. J Hepatol 26: 527-534.
4. Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, et al. (2003) Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 125: 1364-1369.
5. Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H,. (1998) Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 33: 99-103.
6. Kingham JGC, Kochar N, Gravenor MB,. (2004) Incidence, clinical pattern, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 126: 1929-1930.
7. Gossard AA, Angulo P, Lindor KD,. (2005) Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. Am J Gastroenterol 100: 1330-1333. (Pubitemid 40904357)
8. Smith T, Befeler AS,. (2007) High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Curr Gastroenterol Rep 9: 54-59.
9. Charatcharoenwitthaya P, Lindor KD,. (2006) Primary sclerosing cholangitis: diagnosis and management. Curr Gastroenterol Rep 8: 75-82.
10. Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, et al. (2006) 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130: 465-481.
11. Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, et al. (1992) Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 16: 707-714.
12. Lindor KD,. (1997) Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 336: 691-695.
13. van Hoogstraten HJ, Vleggaar FP, Boland GJ, van Steenbergen W, Griffioen P, Hop WC, et al. (2000) Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am J Gastroenterol 95: 2015-2022.
14. Vacca M, Krawczyk M, Petruzzelli M, Sasso RC, van Erpecum KJ, Palasciano G, et al. (2007) Current treatments of primary sclerosing cholangitis. Curr Med Chem 14: 2081-2094.
15. Ishibashi H, Komori A, Shimoda S, Gershwin ME,. (2007) Guidelines for therapy of autoimmune liver disease. Semin Liver Dis 27: 214-226.
16. Stiehl A,. (2006) Primary sclerosing cholangitis: the role of endoscopic therapy. Semin Liver Dis 26: 62-68. (Pubitemid 43320728)
17. Stiehl A, Rost D,. (2005) Endoscopic treatment of dominant stenoses in patients with primary sclerosing cholangitis. Clin Rev Allergy Immunol 28: 159-165.
18. Yamamoto T, Hirohashi K, Kubo S, Tsukamoto T, Uenishi T, Shuto T, et al. (2004) Surgery for segmental primary sclerosing cholangitis. Hepatogastroenterology 51: 668-671.
19. Hirai I, Ishiyama S, Fuse A, Kuzu H, Sakurai F, Kimura S, et al. (2001) Primary sclerosing cholangitis successfully treated by resection of the confluence of the hepatic duct. J Hepatobiliary Pancreat Surg 8: 169-173.
20. Ahrendt SA, Pitt HA, Kalloo AN, Venbrux AC, Klein AS, Herlong HF, et al. (1998) Primary sclerosing cholangitis: resect, dilate, or transplant? Ann Surg 227: 412-423.
21. Van Laethem JL, Devière J, Bourgeois N, Love J, Gelin M, Cremer M, et al. (1995) Cholangiographic findings in deteriorating primary sclerosing cholangitis. Endoscopy 27: 223-228.
22. Björnsson E, Lindqvist-Ottosson J, Asztely M, Olsson R,. (2004) Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 99: 502-508. (Pubitemid 38524130)
23. Meenan J, Rauws EA, Huibregtse K,. (1996) Benign biliary strictures and sclerosing cholangitis. Gastrointest Endosc Clin N Am 6: 127-138.
24. Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, et al. (2005) High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicentre, randomized, controlled study. Gastroenterology 129: 1464-1472.
25. Cook DJ, Mulrow CD, Haynes RB,. (1997) Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med 126: 376-380.
26. Mulrow CD, Oxman AD, eds. (1997) Cochrane Collaboration Handbook. Oxford: Cochrane Library, Update Software.
27. Downs SH, Black N,. (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomized and non-randomized studies of health care interventions. J Epidemiol Community Health 52: 377-384.
28. Ponsioen CY, Lam K, van Milligen de Wit AW, Huibregtse K, Tytgat GN,. (1999) Four years experience with short-term stenting in primary sclerosing cholangitis. Am J Gastroenterol 94: 2403-2407.
29. Stiehl A, Rudolph G, Klöters-Plachky P, Sauer P, Walker S,. (2002) Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 36: 151-156.
30. LaRusso NF, Shneider BL, Black D, Gores GJ, James SP, Doo E, et al. (2006) Primary sclerosing cholangitis: summary of a workshop. Hepatology 44: 746-764.
31. MacCarty RL, LaRusso NF, Wiesner RH,. (1983) Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology 149: 39-44.
32. May GR, Bender CE, LaRusso NF, Wiesner RH,. (1985) Non-operative dilation of dominant strictures in primary sclerosing cholangitis. AJR Am J Roentgenol 145: 1061-1064.
33. van Milligen de Wit AW, Rauws EA, van Bracht J, Mulder CJ, Jones EA, Tytgat GN, et al. (1996) Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc 44: 293-299.
34. Olsson RG, Asztély MS,. (1995) Prognostic value of cholangiography in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 7: 251-254.
35. Tischendorf JJ, Krüger M, Trautwein C, Duckstein N, Schneider A, Manns MP, et al. (2006) Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Endoscopy 38: 665-669.
36. Bergquist A, Broome U,. (2001) Hepatobiliary and extrahepatic malignancies in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol 15: 643-656. (Pubitemid 32747016)
37. Farrant JM, Hayllar KM, Wilkinson ML, Karni J, Portmann BC, Westaby D, et al. (1991) Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 100: 1707-1710.
38. Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD,. (2008) Cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 48: 1106-1117.
39. Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Loof L, Danielsson A, et al. (2002) Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 36: 321-327.
40. Kaya M, de Groen P, Angulo P, Nagorney DM, Gunderson LL, Gores GJ, et al. (2001) Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experience. Am J Gastroenterology 96: 1164-1169.
41. Rosen CB, Nagorney DM, Wiesner RH, Coffey RJ, LaRusso NF,. (1991) Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 213: 21-25.
42. Pohl J, Ring A, Stremmel W, Stiehl A,. (2006) The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 18: 69-74.
43. Lee JG, Schutz SM, England RE, Leung JW, Cotton PB,. (1995) Endoscopic therapy of sclerosing cholangitis. Hepatology 21: 661-667.
44. Bjornsson E, Boberg KM, Cullen S, Fleming K, Clausen OP, Fausa O, et al. (2002) Patients with small duct primary sclerosing cholangitis have favourable longterm prognosis. Gut 51: 731-735.
45. Angulo P, Peter JB, Gershwin ME, DeSotel CK, Shoenfeld Y, Ahmed AE, et al. (2000) Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol 32: 182-187.
46. Mulder AH, Horst G, Haagsma EB, Limburg PC, Kleibeuker JH, Kallenberg CG,. (1993) Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver disease. Hepatology 17: 411-417. (Pubitemid 23072815)
47. Hultcranz R, Olsson R, Danielsson A, Jarnerot G, Loof L, Ryden BO, et al. (1999) A 3-year prospective study on serum tumour markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 30: 669-673.
48. Petersen-Benz C, Stiehl A,. (2005) Impact of dominant stenoses on the serum level of the tumour marker CA 19-9 in patients with primary sclerosing cholangitis. Z Gastroenterol 43: 587-590.
49. Levy MJ, Baron TH, Clayton AC, Enders FB, Gostout CJ, Halling KC, et al. (2008) Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures. Am J Gastroenterol 103: 1263-1273.
50. Nakeeb A, Lipsett PA, Lillemoe KD, Fox-Talbot MK, Coleman J, Cameron JL, et al. (1996) Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma. Am J Surg 171: 147-153. (Pubitemid 26028210)
51. Ahrendt SA, Pitt HA, Nakeeb A, Klein AS, Lillemoe KD, Kalloo AN, et al. (1999) Diagnosis and management of cholangiocarcinoma in primary sclerosing cholangitis. J Gastrointest Surg 3: 357-368.
52. Ponsioen CY, Vrouenraets SM, van Milligen de Wit AW, Sturm P, Tascilar M, Offerhaus GJ, et al. (1999) Value of brush cytology for dominant strictures in primary sclerosing cholangitis. Endoscopy 31: 305-309.
53. Sebo TJ,. (1995) Digital image analysis. Mayo Clin Proc 70: 81-82.
54. Pearsons DL, Takai K, Gibney DJ, Katzmann JA, Lieber MM, Jenkins RB, et al. (1994) Comparison of fluorescence in situ hybridization with flow cytometry and static image analysis in ploidy analysis of paraffin-embedded prostate adenocarcinoma. Hum Pathol 25: 678-683.
55. Moreno Luna LE, Kipp B, Halling KC, Sebo TJ, Kremers WK, Roberts LR, Barr Fritcher EG, Levy MJ, Gores GJ, et al. (2006) Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 131: 1064-1072.
56. Majoie CBLM, Smits NJ, Phoa SSKS, Reeders JWAJ, Jansen PLM,. (1995) Primary sclerosing cholangitis: sonographic findings. Abdom Imaging 20: 109-112.
57. Lee JG, Schutz SM, England RE, Leung JW, Cotton PB,. (1995) Endoscopic therapy of sclerosing cholangitis. Hepatology 21: 661-667.
58. Schulte SJ, Baron RL, Teefey SA, Rohrmann CA, Freeney PC, Shuman WP, et al. (1990) CT of the extrahepatic bile ducts: wall thickening and contrast enhancement in normal and abnormal ducts. AJR Am J Roentgenol 154: 79-85.
59. Macchi V, Floreani A, Marchesi P, Pasini R, Zuliani M, Feltrin GP, et al. (2004) Imaging of primary sclerosing cholangitis: preliminary results by two new non-invasive techniques. Dig Liver Dis 36: 614-621.
60. Eracleous E, Genagritis M, Papanikolaou N, Kontou AM, Prassopoulos H, Allan P, et al. (2005) Complementary role of helical CT cholangiography to MR cholangiography in the evaluation of biliary function and kinetics. Eur Radiol 15: 2130-2139.
61. Silverman WB, Kaw M, Rabinovitz M, Schade RR, Bates BL,. (1994) Complication rate of endoscopic retrograde cholangiopancreatography (ERCP) in patients with primary sclerosing cholangitis (PSC): is it safe? Gastroenterology 106: A359.
62. Moff SL, Kamel IR, Eustace J, Lawler LP, Kantsevoy S, Kalloo AN, et al. (2006) Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. Gastrointest Endosc 64: 219-223.
63. MacCarty RL, LaRusso NF, Wiesner RH,. (1983) Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology 149: 39-44.
64. Hazel SJ, Wolfhagen FHJ, Buuren HR, van de Meeberg PC, van Leeuwen DJ,. (2000) Prospective risk assessment of endoscopic retrograde cholangiography in patients with primary sclerosing cholangitis. Endoscopy 32: 779-782.
65. Harbin WP, Mueller PR, Ferrucci JT,. (1980) Transhepatic cholangiography: complications and use patterns of the fine-needle technique. Radiology 135: 15-22.
66. Cohen SA, Siegel JH, Kasmin FE,. (1996) Complications of diagnostic and therapeutic ERCP. Abdom Imaging 21: 385-394.
67. Moff SL, Kamel IR, Eustace J, Lawler LP, Kantsevoy S, Kalloo AN, et al. (2006) Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. Gastrointest Endosc 64: 219-223.
68. Berstad AE, Aabakken L, Smith HJ, Aasen S, Boberg KM, Schrumpf E,. (2006) Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastroenterol Hepatol 4: 514-520.
69. Boberg KM, Jebsen P, Clausen OP, Foss A, Aabakken L, Schrumpf E,. (2006) Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 45: 568-574.
70. Ahrendt SA,. (2008) Surgical approaches to strictures in primary sclerosing cholangitis. J Gastrointest Surg 12: 423-425.
71. Tsai S, Pawlik TM,. (2009) Primary sclerosing cholangitis: the role of extrahepatic biliary resection. Adv Surg 43: 175-188.
72. May GR, Bender CE, LaRusso NF, Wiesner RH,. (1985) Non-operative dilatation of dominant strictures in primary sclerosing cholangitis. AJR Am J Roentgenol 145: 1061-1064.
73. Baluyut AR, Sherman S, Lehman GA, Hoen H, Chalasani N,. (2001) Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 53: 308-312.
74. Stiehl A, Rudolph G, Kloters-Plachky P, Sauer P, Walker S,. (2002) Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome of endoscopic treatment. J Hepatol 36: 151-156.
75. Van Milligen de Wit AWM, Van Bracht J, Rauws EAJ, Jones EA, Tytgat GNJ, Huibregtse K,. (1996) Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest Endosc 44: 293-299.
76. Dickson ER, Murtaugh PA, Wiesner RH, Grambsch PM, Flemming TR, Ludwig J, et al. (1992) Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 103: 1893-1901.
77. Kaya M, Petersen BT, Angulo P, Baron TH, Andrews JC, Gostout CJ, et al. (2001) Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol 96: 1059-1066.
78. Skolkin MD, Alspaugh JP, Casarella WJ, Chuang VP, Galambos JT,. (1989) Sclerosing cholangitis: palliation with percutaneous cholangioplasty. Radiology 170: 199-206.
79. Graziadei IW, Wiesner RH, Marotta PJ, Porayko MK, Hay JE, Charlton MR, et al. (1999) Longterm results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 30: 1121-1127.
80. Vera A, Moledina S, Gunson B, Hubscher S, Mirza D, Olliff S, et al. (2002) Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 360: 1943-1944.
81. United Network for Organ Sharing (UNOS). UNOS Database. [Accessed 29 February 2008.
82. Myburgh JA,. (1994) Surgical biliary drainage in primary sclerosing cholangitis: the role of the Hepp-Couinaud approach. Arch Surg 129: 1057-1062.
83. Pitt HA, Thompson HH, Tompkins RK, Longmire WP,. (1982) Primary sclerosing cholangitis: results of an aggressive surgical approach. Ann Surg 196: 259-268.
84. Martin FM, Rossi RL, Nugent FW, Scholz FJ, Jenkins RL, Lewis WD, et al. (1990) Surgical aspects of sclerosing cholangitis. Results in 178 patients. Ann Surg 212: 551-556.
85. Ismail T, Angrisani L, Powell JE, Hübscher S, Buckels J, Neuberger J, et al. (1991) Primary sclerosing cholangitis: surgical options, prognostic variables, and outcome. Br J Surg 78: 564-567.
86. Farges O, Malassagne B, Sebaugh M, Bismuth H,. (1995) Primary sclerosing cholangitis: liver transplantation or biliary surgery. Surgery 117: 146-155.
87. Brandsaeter B, Friman S, Broomé U, Isoniemi H, Olausson M, Bäckman L, et al. (2003) Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scand J Gastroenterol 38: 1776-1783.
88. Martin FM, Rossi RL, Nugent FW, Scholz FJ, Jenkins RL, Lewis WD, et al. (1990) Surgical aspects of sclerosing cholangitis. Results in 178 patients. Ann Surg 212: 551-556.
89. Ismail T, Angrisani L, Powell JE, Hübscher S, Buckels J, Neuberger J, et al. (1991) Primary sclerosing cholangitis: surgical options, prognostic variables, and outcome. Br J Surg 78: 564-567.
90. Farges O, Malassagne B, Sebaugh M, Bismuth H,. (1995) Primary sclerosing cholangitis: liver transplantation or biliary surgery. Surgery 117: 146-155.
91. Brandsaeter B, Friman S, Broomé U, Isoniemi H, Olausson M, Bäckman L, et al. (2003) Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scand J Gastroenterol 38: 1776-1783.
92. Ahrendt SA, Pitt HA, Kalloo AN, Venbrux AC, Klein AS, Herlong HF, et al. (1998) Primary sclerosing cholangitis: resect, dilate, or transplant? Ann Surg 227: 412-423.
93. Linder S, Söderlund C,. (2001) Endoscopic therapy in primary sclerosing cholangitis: outcome of treatment and risk of cancer. Hepatogastroenterology 48: 387-392.
94. Chalasani N, Baluyut A, Ismail A, Zaman A, Sood G, Ghalib R, et al. (2000) Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicentre case-control study. Hepatology 31: 7-11.